Trevena, Inc.
1018 West 8th Avenue
Suite A
King of Prussia
Pennsylvania
19406
United States
Tel: 610-354-8840
Website: http://www.trevenainc.com/
Email: IR@trevenainc.com
170 articles with Trevena, Inc.
-
As drugmakers continue to develop an understanding of what pain is to the human body, it helps drive the development of innovative manners to treat it that transcend addictive options such as opioids.
-
The U.S. Food and Drug Administration issued a Complete Response Letter to the company in November, one month after an advisory committee rejected the drug. When the FDA issued the CRL, the regulatory agency requested additional clinical data on QT prolongation and indicated that the submitted sa...
-
Johnson Fistel Files Class Action Suit Against Trevena, Inc.
11/17/2018
Johnson Fistel, LLP announced that a class action has been commenced on behalf of purchasers of Trevena, Inc. (NASDAQ:TRVN) common stock during the period between May 2, 2016 and October 9, 2018 (the "Class Period").
-
In the wake of a Complete Response Letter issued by the FDA, Trevana, Inc. is slashing one-third of its workforce. On Wednesday, Merrimack Pharmaceuticals also announced it was terminating 60 percent of its staff as the company narrows its research and development focus.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
As we end October and head into November, the Food and Drug Administration (FDA) continues its work. This upcoming week has several PDUFA action dates for drug applications. Here’s a look.
-
Things seem to have gone from bad to worse for Pennsylvania-based Trevena, Inc. This week the company saw a U.S. Food and Drug Administration advisory committee reject its intravenous pain treatment and now a class action lawsuit filed against the company claims Trevena executives have misled inv...
-
Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Are Encouraged to Contact The Firm
10/11/2018
Block & Leviton LLP announces that it has filed a securities fraud class action against Trevena, Inc. and certain of its officers alleging violations of the federal securities laws and encourages shareholders to contact Block & Leviton ahead of the December 10, 2018 lead plaintiff deadline.
-
INVESTOR ALERT: Investigation of Trevena Announced by Holzer & Holzer, LLC
10/11/2018
Holzer & Holzer, LLC is investigating whether certain statements issued by Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) complied with federal securities laws.
-
Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director
7/31/2018
Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the oncology field announces today the appointment of Barbara Yanni to its Board of Directors as an Independent Director.
-
Trevena Promotes Carrie Bourdow to Executive Vice President and COO
2/2/2018
Ms. Bourdow brings to this newly created position over 25 years of experience at large and small commercial biopharmaceutical companies.
-
Trevena Announces FDA Acceptance for Review of New Drug Application for OLINVO (oliceridine) Injection
1/2/2018
OLINVO is an investigational product for the management of moderate to severe acute pain.
-
Trevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial Data
11/7/2017
The company announced positive new data from both its OLINVOTM (oliceridine injection) and TRV250 programs.
-
Trevena Announces Submission of New Drug Application to FDA for OLINVO (oliceridine injection)
11/2/2017
The filing is supported by positive Phase 3 APOLLO and ATHENA studies.
-
Trevena to Report Third Quarter 2017 Financial Results on November 7, 2017
11/1/2017
To join the call, please dial-in at (855) 465-0180 (conference ID: 9796968).
-
Trevena Announces Publication and Presentations of OLINVO (oliceridine injection) Clinical Data
10/26/2017
The Company also announced that results of its Phase 2b trial of Breakthrough Therapy-designated OLINVO (oliceridine injection) have been published in the peer-reviewed Journal of Pain Research.
-
Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/1/2017
-
Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/15/2017
-
Trevena Reports Second Quarter 2017 Financial Results and Provides Corporate Update
8/3/2017